论文部分内容阅读
目的:观察前痛定方对Ⅲb型前列腺炎(CP)患者血浆中单胺类神经递质水平的影响。方法:120例Ⅲb型CP患者采用区组随机化方法分配到G1组、G2组和G3组。G1组口服前痛定方;G2组口服可多华片;G3组口服前痛定方及可多华片,疗程均为30 d。治疗前后对所有患者进行前列腺症状评分(NIH-CPSI)、ELISA法检测血浆中单胺类神经递质肾上腺素(NE)、5-羟色胺(5-HT)、多巴胺(DA)水平。结果:治疗前三组间基线特征均衡性良好(P>0.05);治疗后三组NIH-CPSI评分、血浆NE、DA水平降低、血浆5-HT水平升高,但G3组较G1、G2组为佳(P<0.05)。结论:前痛定方能够明显地降低Ⅲb型CP患者NIH-CPSI评分,恢复Ⅲb型CP患者异常的血浆单胺类神经递质水平,显著地改善Ⅲb型CP患者的临床症状。
Objective: To observe the effect of Qian pain decoction on monoamine neurotransmitter levels in patients with type Ⅲb prostatitis (CP). Methods: One hundred and twenty patients with type Ⅲ b CP were assigned to G1, G2 and G3 using block randomized method. Group G1 before oral administration of pain; Group G2 oral can be more Chinese films; G3 group before oral administration of pain and can be more films, treatment were 30 d. Prostate symptom scores (NIH-CPSI) were measured in all patients before and after treatment. Levels of monoamine neurotransmitters, including NE, 5-HT and DA, were measured by ELISA. Results: The baseline characteristics of the three groups before treatment were well balanced (P> 0.05). After treatment, the levels of NIH-CPSI, NE and DA in plasma and plasma 5-HT levels were increased in G3 group Better (P <0.05). Conclusion: QianTongDing Decoction can significantly reduce the level of NIH-CPSI in type Ⅲ b CP patients and restore abnormal plasma levels of monoamine neurotransmitter in type Ⅲ b CP patients, and significantly improve the clinical symptoms of type Ⅲ b CP patients.